Showing 1-10 of about 264 articles.
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 17, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that the United States Patent and Trademark Office (“USPTO”) has...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 08, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it has filed a new provisional patent application at the United...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 12, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or the “Company”) today announced that its Board of Directors appointed...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) ("Company" or "IntelGenx") today announced the execution of a definitive supply agreement (the...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 06, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Corporation” or “IntelGenx”) announced that on December 31, 2020, it issued...
IntelGenx Technologies Corp.
SAINT-LAURENT, Quebec, Dec. 08, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 899,940 common...
IntelGenx Technologies Corp.
SAINT-LAURENT, Quebec, Nov. 23, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company’s board of directors...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 12, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter...
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 11, 2020 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent...
IntelGenx Technologies Corp.
- Data Suggest Montelukast May Inhibit Mental Decline, Higher Doses Optimal for Clinical Trials Assessing Impact on Neurological Disease - SAINT LAURENT, Quebec, Nov. 09, 2020 (GLOBE NEWSWIRE) --...
Showing 1-10 of about 264 articles.
